IMMUNITYBIO, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
IMMUNITYBIO, INC. (IBRX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $2.92 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-07
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $2.92M, a 81.79% decline year-over-year.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $19.73M.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $6.96M, a 1.55% increase year-over-year.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $56.82M.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $99.55M.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$113.67M.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$175.22M.
- IMMUNITYBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$235.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | $2.92M 10-Q · filed 2018-05-07 | $22.65M derived: sum of 2 quarters · filed 2018-05-07 | $29.61M derived: sum of 3 quarters · filed 2018-05-07 | $86.43M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-12-31 | $19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $26.70M derived: sum of 2 quarters · filed 2018-03-12 | $83.51M derived: sum of 3 quarters · filed 2018-03-12 | $99.55M 10-K · filed 2018-03-12 | ||
| 2017-09-30 | $6.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $63.78M derived: sum of 2 quarters · filed 2017-11-07 | $79.82M 10-Q · filed 2017-11-07 | $71.35M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-06-30 | $56.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $72.86M 10-Q · filed 2017-08-07 | $64.39M derived: sum of 3 quarters · filed 2018-05-07 | $71.25M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2017-03-31 | $16.04M 10-Q · filed 2018-05-07 | $7.57M derived: sum of 2 quarters · filed 2018-05-07 | $14.43M derived: sum of 3 quarters · filed 2018-05-07 | $4.28M derived: sum of 4 quarters · filed 2018-05-07 | ||
| 2016-12-31 | -$8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$1.61M derived: sum of 2 quarters · filed 2018-03-12 | -$11.76M derived: sum of 3 quarters · filed 2018-03-12 | -$113.67M 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $6.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$3.30M derived: sum of 2 quarters · filed 2017-11-07 | -$105.21M 10-Q · filed 2017-11-07 | -$277.33M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-06-30 | -$10.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$112.06M 10-Q · filed 2017-08-07 | -$284.18M derived: sum of 3 quarters · filed 2018-03-12 | -$284.83M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2016-03-31 | -$101.91M 10-Q · filed 2017-05-08 | -$274.03M derived: sum of 2 quarters · filed 2018-03-12 | -$274.68M derived: sum of 3 quarters · filed 2018-03-12 | -$275.28M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2015-12-31 | -$172.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$172.77M derived: sum of 2 quarters · filed 2018-03-12 | -$173.37M derived: sum of 3 quarters · filed 2018-03-12 | -$175.22M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | -$651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$1.25M derived: sum of 2 quarters · filed 2016-11-10 | -$3.10M 10-Q · filed 2016-11-10 | -$3.25M 10-Q · filed 2015-11-12 | -$3.13M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$2.45M 10-Q · filed 2016-08-15 | -$2.57M 10-Q · filed 2015-09-10 | -$2.48M derived: sum of 3 quarters · filed 2017-03-15 | -$2.67M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$1.86M 10-Q · filed 2016-05-16 | -$1.89M derived: sum of 2 quarters · filed 2017-03-15 | -$2.07M derived: sum of 3 quarters · filed 2017-03-15 | -$2.09M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$30.00K derived: 10-K 12 month − 10-K 9 month · filed 2017-03-15 | -$218.00K derived: sum of 2 quarters · filed 2017-03-15 | -$237.00K derived: sum of 3 quarters · filed 2017-03-15 | -$235.00K 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$188.00K derived: 10-K 9 month − 10-K 6 month · filed 2016-03-30 | -$207.00K derived: sum of 2 quarters · filed 2016-03-30 | -$205.00K 10-K · filed 2016-03-30 | -$251.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$19.00K derived: 10-K 6 month − 10-K 3 month · filed 2016-03-30 | -$17.00K 10-K · filed 2016-03-30 | ||||
| 2014-03-31 | $2.00K 10-K · filed 2016-03-30 | |||||
| 2013-12-31 | -$3.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |